Malignant Phyllodes Tumor of the Breast: A Case Report

Mohammed Al-Zoubaidi1, Suimin Qiu2,5, Mark Bonnen6, Melissa Joyner3, Kendall Roehl4, Colleen Silva1 and Celia Chao*,1,5

Departments of 1Surgery, 2Surgical Pathology, 3Radiation Oncology, 4Plastic Surgery, 5Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, Galveston, Texas, USA; 6Department of Radiation Oncology, Brazosport Regional Health System, Lake Jackson, Texas, USA

Abstract: Phyllodes tumors of the breast have biphasic histological features with both epithelial and stromal components. Careful characterization of the stromal compartment is critical since it is the pathologic features of the stromal cells that determine its malignant potential. We present a case report of a woman with an aggressive malignant phyllodes tumor with sarcomatous differentiation, who succumbed to metastatic disease within 8 months of initial presentation.

Keywords: Spindle cell tumors, high-grade sarcoma component, malignant phyllodes, malignant fibrous histiocytoma, osteosarcoma.

INTRODUCTION

Phyllodes tumors (PT), previously called cystosarcoma phyllodes, are fibroepithelial tumors of the breast, representing 2-3% of all fibroepithelial tumors, and less than 1% of all breast tumors [1]. PT are uniquely found in breast tissue and histologically have both an epithelial component as well as metaplastic mesenchymal (stromal) component. Clonal analyses have revealed that some PT develop from fibroadenomas [2]. At least 12.5% of patients with PT have a history of fibroadenomas and over 20% of patients have a concurrent diagnosis of a benign fibroadenoma [3]. The pathological appearance of stromal overgrowth, stromal cellularity, degree of nuclear atypia, number of mitotic cells, and the nature of the tumor margin (circumscribed, pushing, or infiltrative) determines whether a tumor is a benign fibroadenoma, a benign PT, a borderline PT, or a malignant PT. The stroma from malignant PT are distinguished by marked cellularity with nuclear atypia, nuclear pleomorphism, increased mitotic activity, and stromal cell overgrowth [4, 5]. Heterogeneous stromal components are seen in PT and is commonly associated with malignant PT [4, 6, 7]. Malignant PT has a 5- and 10-year overall survival of 84% and 77% after surgical extirpation [8].

In the present report, we discuss a patient who presented with a malignant PT with sarcomatous elements. She developed multiple large pulmonary metastases and brain metastases and expired within 8 months of initial presentation and diagnosis.

CASE REPORT

A 59-year-old Hispanic female was referred to our breast clinic for evaluation of a large left breast mass, which had been palpable for the past three years. The breast mass began to rapidly increase in size and became painful in the past year, and within the past 3 months prior to consultation, the breast mass grew significantly larger and eroded through the overlying skin. A core needle biopsy from an outside hospital reported a “malignant phyllodes tumor”. She was postmenopausal, Gravida 5 Para 5, with a family history of breast cancer in her two maternal aunts who both died of the disease at 40 and 50 years of age, respectively.

On physical examination, she had a left 20 x 20 cm multilobulated breast mass visible on the left side with erosion through the skin medially (Fig. 1). The contralateral breast examination was unremarkable. There was no palpable cervical, supraclavicular, or axillary lymphadenopathy. There was no clinical suspicion for distant disease. She underwent a total mastectomy with en-bloc partial pectoralis major muscle resection to ensure an adequate resection margins; a fasciocutaneous advancement flap was performed to achieve wound closure. She had an uneventful recovery and she was discharged on postoperative day two.

Final pathology report confirmed a malignant phyllodes breast tumor measuring 24 cm in greatest dimension; on cut surface, there was white and tan tissue with areas of hemorrhage and necrosis (Fig. 2). Microscopically, a leaf-like pattern, characteristic of phyllodes, was seen focally at the edge of the tumor (Fig. 3A). The tumor consisted of mainly high-grade sarcoma with hypercellularity and necrosis (Fig. 3B). The heterologous components were comprised mainly of high-grade sarcoma (malignant fibrous histiocytoma-like, Fig. 3C) with high mitotic index (16 mitoses/10 HPF, Fig. 3C), osteosarcoma (5%, Fig. 3D) and chondrosarcoma (<5%, not shown). There was no evidence of lymphovascular invasion, and all resection margins were free of the tumor. Two enlarged lymph nodes, found intraoperatively, were removed with the specimen, and were negative for malignancy on histopathology.
Fig. (1). The patient with a very large left breast mass with prominent, enlarged veins overlying the tumor, at initial clinical presentation.

Fig. (2). Cross section of the tumor revealing a white-tan fleshy tumor with focal areas of necrosis and hemorrhage.

Fig. (3). Histologic features of the tumor. (A) Areas with phyllodes or leaf-like pattern with characteristic biphasic features: epithelial and stromal components. (B) The overgrowth of the high-grade sarcoma has extensive coagulative necrosis, and (C) hypercellular spindle cell proliferation with nuclear atypia and active mitotic figures. (D) Malignant sarcoma with osteoid production was in a portion of the tumor, indicating the presence of an osteosarcomatous component in this malignant PT.
A postoperative CT scan revealed large bilateral lung metastases (Fig. 4); needle biopsy confirmed a spindle cell neoplasm consistent with metastasis. Within 5 weeks of mastectomy, she complained of headaches and a head CT scan identified an 11 mm right parietal lobe-enhancing lesion in the brain, consistent with a metastatic deposit. She was treated with a Doxorubicin-based chemotherapy and gamma knife radiosurgery to the brain. The disease progressed during the next six months and she expired in hospice care 8 months after her initial presentation.

**DISCUSSION**

Standard treatment for all PT requires a minimum of a 1 cm clear margin [9]. Because malignant PT rarely metastasize to regional lymph nodes [10], sentinel node biopsy is not indicated. The routine use of adjuvant chemotherapy and/or radiation therapy is not recommended for malignant PT since neither modality has shown an improvement in overall survival. In this patient, however, the size of tumor places the patient at very high risk of local recurrence, and thus adjuvant radiation therapy was considered. Moreover, she developed metastatic pulmonary and brain lesions and was offered palliative chemotherapy. The use of systemic therapy for metastatic disease of PT is based on the guidelines for treating sarcomas, not breast carcinoma. Since only the stromal component metastasizes, the metastatic deposits resemble sarcomas [11]. The incidence of metastases from malignant PT ranges from 6.2% [12] to 25% [3, 13].

Malignant PT with differentiated sarcomatous components as a portion of the stromal tumor have been reported: osteosarcoma [14], liposarcoma [15, 16], leiomyosarcoma [17], fibrosarcoma [18], chondrosarcoma [19], rhabdosarcoma [20] and malignant fibrous histiocytoma [21]. In a review of all reported cases of metastatic PT (67 cases) prior to 1972, Kessinger and colleagues [22] noted that the average survival time after diagnosis of metastasis was 30 months. Metastatic lesions have been reported as early as at the initial diagnosis of the primary tumor and as late as 12 years after diagnosis. The longest survival time after diagnosis with metastatic disease was 14.5 years. The most common site of the initially diagnosed distant metastasis was the lungs. Other metastatic sites include the bones, liver, heart, and distant lymph nodes [23]. Rarely, direct extension without distant metastases may result in death [24, 25]. As with soft tissue sarcomas, in general, distant pulmonary metastases may be resectable for possible cure, if it is the only site of distant disease [4, 26].

Malignant PT rarely metastasize to the central nervous system [27]; however, when present, widespread metastases is common. In a report by Hlavin et al., [27], the mean interval from initial diagnosis to CNS metastasis is 5 years with a range of 3.5 months and 14 years. Prognosis is universally poor with a mean survival of 29 days after diagnosis of CNS involvement system.

In summary, malignant PT represent less than 1% of all breast malignancies and commonly have an indolent clinical course with a propensity for local recurrence. Adequate histologic sampling of the stromal tissue is necessary for diagnosis of malignant PT. Rarely, malignant PT can behave very aggressively once hematogenous dissemination to the brain has been diagnosed. We present an unusual case of malignant PT with pulmonary and brain metastases treated...
with palliative mastectomy, chemotherapy, and radiosurgery to the brain.

ACKNOWLEDGEMENT

None declared.

CONFLICTS OF INTEREST

None declared.

REFERENCES